nach oben

AIDS and Behavior

Erschienen in:

01.01.2015 | Original Paper

Depressive Symptoms, Lifestyle Structure, and ART Adherence Among HIV-Infected Individuals: A Longitudinal Mediation Analysis

verfasst von: Jessica F. Magidson, Aaron J. Blashill, Steven A. Safren, Glenn J. Wagner

Erschienen in: AIDS and Behavior | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Despite the well-documented relationship between depression and antiretroviral therapy (ART) nonadherence, few studies have identified explanatory pathways through which depression affects adherence. The current study tested lifestyle structure—the degree of organization and routinization of daily activities—as a mediator of this relationship, given previous evidence of lifestyle structure being associated with both depression and ART nonadherence. HIV-infected individuals starting or re-starting ART in the California Collaborative Treatment Group 578 study (n = 199) were assessed over 48 weeks. Adherence was measured using electronic monitoring caps to determine dose timing and doses taken, and viral load was assessed. The mediating role of lifestyle structure was tested using generalized linear mixed-effects modeling and bootstrapping. Lifestyle significantly mediated the relationship between depression and both measures of ART adherence behavior. Interventions that minimize disruptions to lifestyle structure and link adherence to daily activities may be useful for individuals with depression and ART nonadherence.

Genberg BL, Wilson IB, Bangsberg DR, et al. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS. 2012;26:1415–23.PubMedCentralPubMedCrossRef

de García Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30:105–10.CrossRef

Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother. 2011;45:372–9.PubMedCrossRef

Martin M, Del Cacho E, Codina C, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: A prospective cohort study. AIDS Res Hum Retrovir. 2008;24:1263–8.PubMedCrossRef

Bangsberg DR. Less than 95 % adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939–41.PubMedCrossRef

Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793–800.PubMedCentralPubMedCrossRef

Kacanek D, Jacobson DL, Spiegelman D, Wanke C, Isaac R, Wilson IB. Incident depression symptoms are associated with poorer HAART adherence: a longitudinal analysis from the Nutrition for Healthy Living study. J Acquir Immune Defic Syndr. 2010;53:266–72.PubMedCentralPubMedCrossRef

Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58:181–7.PubMed

Wagner GJ, Goggin K, Remien RH, et al. A closer look at depression and its relationship to HIV antiretroviral adherence. Ann Behav Med. 2011;42:352–60.PubMedCentralPubMedCrossRef

10.

Lima VD, Geller J, Bangsberg DR, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS. 2007;21:1175–83.PubMedCrossRef

11.

Blashill A, Gordon J, Mimiaga M. HIV/AIDS and depression. In: Richards S, O’Hara M, editors. The Oxford handbook of depression and comorbidity. New York: Oxford University Press; 2014.

12.

Carvalho JP, Gawrysiak MJ, Hellmuth JC, et al. The reward probability index: design and validation of a scale measuring access to environmental reward. Behav Ther. 2011;42:249–62.PubMedCrossRef

13.

Hopko DR, Lejuez CW, Ruggiero KJ, Eifert GH. Contemporary behavioral activation treatments for depression: procedures, principles, and progress. Clin Psychol Rev. 2003;23:699–717.PubMedCrossRef

14.

Hopko DR, Mullane CM. Exploring the relation of depression and overt behavior with daily diaries. Behav Res Ther. 2008;46:1085–9.PubMedCrossRef

15.

Kanter JW, Rusch LC, Busch AM, Sedivy SK. Validation of the behavioral activation for depression scale (BADS) in a community sample with elevated depressive symptoms. J Psychopathol Behav Assess. 2009;31:36–42.CrossRef

16.

Lewinsohn PM. A behavioral approach to depression. In: Friedman RJ, Katz MM, editors. The psychology of depression: contemporary theory and research. Oxford: John Wiley & Sons; 1974. p. 318.

17.

Lewinsohn PM, Graf M. Pleasant activities and depression. J Consult Clin Psychol. 1973;41:261–8.PubMedCrossRef

18.

Ferster C. A functional analysis of depression. Am Psychol. 1973;28:857–70.PubMedCrossRef

19.

MacPhillamy C, Lewinsohn PM. The pleasant events schedule. Eugene: University of Oregon; 1971.

20.

Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12:255–66.PubMedCrossRef

21.

Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386–95.PubMedCrossRef

22.

Roberts KJ. Barriers to and facilitators of HIV-positive patients’ adherence to antiretroviral treatment regimens. AIDS Patient Care STDs. 2000;14:155–68.PubMedCrossRef

23.

Wagner GJ, Ryan GW. Relationship between routinization of daily behaviors and medication adherence in HIV-positive drug users. AIDS Patient Care STDs. 2004;18:385–93.PubMedCrossRef

24.

Wenger N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral adherence. Presented at the 6th Conference on Retroviruses and Opportunistic Infections; 1999; Chicago.

25.

Ryan GW, Wagner GJ. Pill taking “routinization”: a critical factor to understanding episodic medication adherence. AIDS Care. 2003;15:795–806.PubMedCrossRef

26.

Wagner GJ, Kanouse DE, Golinelli D, et al. Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578). AIDS. 2006;20:1295–302.PubMedCrossRef

27.

Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357–66.PubMedCrossRef

28.

Safren SA, O’Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. 2012;80:404–15.PubMedCentralPubMedCrossRef

29.

Derogatis LR. BSI 18, Brief symptom inventory 18: administration scoring and procedures manual. Iowa: NCS Pearson Incorporated; 2001.

30.

Tchekmedyian NS, Kallich J, McDermott A, Fayers P, Erder MH. The relationship between psychological distress and cancer-related fatigue. Cancer. 2003;98:198–203.PubMedCrossRef

31.

Wagner GJ, Remien RH, Carballo-Diéguez A, Dolezal C. Correlates of adherence to combination antiretroviral therapy among members of HIV-positive mixed status couples. AIDS Care. 2002;14:105–9.PubMedCrossRef

32.

Selig JP, Preacher KJ. Mediation models for longitudinal data in developmental research. Res Hum Dev. 2009;6:144–64.CrossRef

33.

Kraemer H, Kiernan M, Essex M, Kupfer DJ. How and why criteria defining moderators and mediators differ between the Baron & Kenny and MacArthur approaches. Health Psychol. 2008;27:S101–8.PubMedCentralPubMedCrossRef

34.

MacKinnon D. Introduction to statistical mediation analysis. Routledge: CRC Press; 2007.

35.

Bauer DJ, Preacher KJ, Gil KM. Conceptualizing and testing random indirect effects and moderated mediation in multilevel models: new procedures and recommendations. Psychol Methods. 2006;11:142–63.PubMedCrossRef

36.

MacKinnon DP, Lockwood CM, Williams J. Confidence limits for the indirect effect: distribution of the product and resampling methods. Multivar Behav Res. 2004;39:99.CrossRef

37.

Shrout PE, Bolger N. Mediation in experimental and nonexperimental studies: new procedures and recommendations. Psychol Methods. 2002;7:422–45.PubMedCrossRef

38.

Preacher KJ, Hayes AF. SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav Res Methods Instrum Comput. 2004;36:717–31.PubMedCrossRef

39.

Hayes AF. Beyond Baron and Kenny: statistical mediation analysis in the new millennium. Commun Monogr. 2009;76:408–20.CrossRef

40.

Lejuez CW, Hopko DR, Acierno R, Daughters SB, Pagoto SL. Ten year revision of the brief behavioral activation treatment for depression: revised treatment manual. Behav Modif. 2011;35:111–61.PubMedCrossRef

41.

Daughters SB, Magidson JF, Schuster RM, Safren SA. ACT HEALTHY: a combined cognitive-behavioral depression and medication adherence treatment for HIV-infected substance users. Cogn Behav Pr. 2010;17:309–21.CrossRef

42.

Safren SA, O’Cleirigh C, Tan JY, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009;28:1–10.PubMedCentralPubMedCrossRef

43.

Safren SA, Otto MW, Worth JL, et al. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Res Ther. 2001;39:1151–62.PubMedCrossRef

44.

Paterson DL, Swindells S. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21.PubMedCrossRef

Titel: Depressive Symptoms, Lifestyle Structure, and ART Adherence Among HIV-Infected Individuals: A Longitudinal Mediation Analysis
verfasst von: Jessica F. Magidson
Aaron J. Blashill
Steven A. Safren
Glenn J. Wagner
Publikationsdatum: 01.01.2015
Verlag: Springer US
Erschienen in: AIDS and Behavior / Ausgabe 1/2015
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-014-0802-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Selective Disclosure of HIV Status in Egocentric Support Networks of People Living with HIV/AIDS

HIV Stigma and Physical Health Symptoms: Do Social Support, Adaptive Coping, and/or Identity Centrality Act as Resilience Resources?

HIV Testing Behaviors and Attitudes Among Community Recruited Methamphetamine Users in a South African Township

The Factor Structure and Presentation of Depression Among HIV-Positive Adults in Uganda

The Unique Challenges Facing HIV-Positive Patients Who Smoke Cigarettes: HIV Viremia, Art Adherence, Engagement in HIV care, and Concurrent Substance Use